COGT250117P14000
- 3.00
- 0.000.00%
Cogent Biosciences Newsroom
Is Cogent Biosciences (NASDAQ:COGT) In A Good Position To Invest In Growth?
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Cogent Biosciences (COGT) Gets a Buy From J.P. Morgan
Express News | Cogent Biosciences Inc : JP Morgan Raises Target Price to $23 From $21
Needham Downgrades Cogent Biosciences to Hold, Maintains Price Target to $15
Express News | Cogent Biosciences Inc : Needham Cuts to Hold From Buy
Needham Downgrades Cogent Biosciences(COGT.US) to Hold Rating, Maintains Target Price $15
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $17
Cogent Biosciences Price Target Maintained With a $15.00/Share by Needham
Cogent Biosciences Analyst Ratings
Leerink Partners Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $16
Promising Market Potential for Cogent Biosciences: A Buy Rating Backed by Efficacy and Safety of Bezuclasinib
Why Is Cogent Biosciences Stock Trading Higher On Monday?
Express News | Cogent Biosciences Inc : Leerink Partners Raises Target Price to $16 From $15
Express News | Cogent Biosciences Shares Are Trading Lower. The Company Presented Data on Bezuclastinib for Mastocytosis at ASH 2024
Cogent Biosciences Reports Updated Results From Trial of Bezuclastinib
Express News | Cogent Biosciences Inc: Top-Line Results Now Expected in July 2025
Express News | Cogent Biosciences: 56% Mean Improvement in Total Symptom Score at 24 Weeks With 76% of Patients Achieving at Least a 50% Reduction in Tss
Express News | Cogent Biosciences: Updated Clinical Results From Open Label Extension Portion of Summit Trial
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15